to experience the full functionality of mail.com.
Enhanced by Google
Gilead Sciences Inc
May 05, 2016
Merck beats 1Q profit views with tight cost controls
Merck posted an 18 percent jump in first-quarter income, beating Wall Street expectations, as reduced spending on marketing, ...
April 19, 2016
Johnson & Johnson rides strong prescription sales in 1Q
Johnson & Johnson beat Wall Street expectations despite flat first-quarter profit, as higher sales of new prescription drugs ...
April 04, 2016
Gilead paying up to $1.2B for Nimbus unit, drug candidate
Biologic drugmaker Gilead Sciences Inc. said Monday that it will buy a subsidiary of Nimbus Therapeutics LLC and its ...
March 25, 2016
Jury: Gilead owes Merck $200M in damages over drug patents
The federal jury in a patent trial has ordered drugmaker Gilead Sciences to pay Merck $200 million in damages for infringing ...
March 22, 2016
Jury finds for Merck in hepatitis drug fight with Gilead
A federal jury in California has ruled in favor of drugmaker Merck & Co. in a high-stakes lawsuit against rival Gilead ...
January 28, 2016
FDA OKs Merck hepatitis C drug, adding to patient choices
Patients with hepatitis C have yet another advanced treatment option, as the Food and Drug Administration on Thursday ...
January 27, 2016
Massachusetts is investigating high cost of hepatitis C drug
The Massachusetts attorney general's office said Wednesday that it is investigating whether the makers of a breakthrough ...
December 01, 2015
Report: Drug maker was focused on profits, not patients
The makers of a breakthrough hepatitis drug put profits before patients in pricing the $1,000 pill that's become a symbol of ...